Summary We studied outcomes of mammographic screening in women older than 65 years. In 1975, breast cancer screening was started in Nijmegen, The Netherlands, for women aged 35-65 years. Since 1977, approximately 7700 older women have also been invited for biennial one-view mammography. This report is based on ten screening rounds from 1975 to 1994. The results of the subsequent screening rounds in the age groups 65-69 years, 70-74 years and 75 years and older were: participation rates 55%, 39% and 15%; screendetected cancer rates 5.6%o, 6.9%o and 7.8%o; interval cancer rates 2.0%oo, 1.8%o and 3.5%o; and predictive values of referral 62%, 64% and 62% respectively. In all age groups, screen-detected patients had smaller tumours and a lower prevalence of axillary lymph node involvement than unscreened patients. Our conclusion is that, in women aged 65 years and older, breast cancer can be detected at an earlier stage by mammographic screening.
Breast cancer is the commonest malignancy in women. The incidence of invasive breast cancer in The Netherlands rises with age to about 340 new diagnosis annually per 100 000 women aged 70 years and older (Netherlands Cancer Registry, 1995) . Approximately one out of three new cases of invasive breast cancer is diagnosed in this age group. Although it has often been argued that this disease is more indolent in older women, their relative survival is no better than for younger women (Yancik et al., 1989) .
Several trials have been conducted, and reviews of the results show that mammographic screening can reduce breast cancer mortality by approximately 30% (Fletcher et al., 1993; Nystr6m et al., 1993; De Koning et al., 1995a) . Recently, it was shown that mammographic screening of women aged 65-74 years can also reduce breast cancer mortality (Van Dijck et al., 1994 , 1996 Chen et al., 1995) .
To evaluate screening programmes that may have differently aged target populations, background material is necessary in order to assess the early results. For women aged 50 -69 years, this information is available from several regional and national programmes (Peer et al., 1994; Tabar et al., 1993; De Koning et al., 1995b; Chamberlain et al., 1993) , but for older age groups, information is limited.
The aim of the present study was to determine age-specific outcomes of mammographic screening, with emphasis on women aged 65 years and older, in the Nijmegen programme, which is the only long-running trial in the world that included women over 75 years of age (Otten et al., 1996) .
Study population and methods
In 1975, a population-based screening programme for breast cancer was started in Nijmegen, The Netherlands. In 1975 and 1976 , approximately 30 000 women aged 35-65 years received their first invitation to participate in the mass mammographic screening. From the second round onwards, some 7700 older women were also invited for biennial oneview mammography. From 1975 up to 1994, ten screening rounds were carried out. Details of the programme and the round-specific results up to round 9 will be published elsewhere (Otten et al., 1996) .
The present analyses concerned primary breast cancer patients diagnosed before December 1994. Excluded were patients with lobular carcinoma in situ, patients diagnosed before their first invitation to screening and women under the age of 50. Age, defined as the age on the date of invitation, was categorised as 50-64, 65-69, 70-74 Table I shows the number of invitations and the participation rates, referral rates and cancer rates for the first invitation. The participation rates for the first invitation decreased dramatically at older ages from 81% in women aged 50 -64 years to 24% in women aged 75 years and older, while those for the subsequent invitations were some 10% lower at all ages. Table II shows corresponding details for subsequent invitations. The initial high rates of referral and detection (18% and 9%) dropped in the subsequent invitations to levels of about 10 and 6 per 1000 accepted invitations in women aged 65 years and older. The breast cancer detection rates in women who had been screened regularly (i.e. those also screened in the previous round) remained fairly high at 3.0, 5.5, 6.0 and 6.3 per 1000 accepted invitations for the four age groups (not included in the tables). Interval cancer rates were slightly higher after subsequent invitations than after the first invitation. The non-participant cancer rates did not increase in the older age groups. The predictive value of referral was Mammographic screening outcomes in elderly women JAAM van Dijck et at %P 1839 very high. At subsequent invitations, breast cancer was diagnosed in two out of three referred women aged 65 and older. The ratio of screen-detected cancers to the sum of screen-detected plus interval cancers was 0.69 or higher in women older than age 65. , 1996) . In Stockholm, similar results were reported in participants and non-participants aged 40-64 years (Lidbrink et al., 1995) . It is possible that participants had fewer co-existing diseases or that these were less severe. There may even be an interaction between breast cancer and certain co-existing diseases. In breast cancer patients with localised or regional disease, Satariano and Ragland (1994) found that the probability of survival decreased with an increasing number of co-existing conditions, whereas in patients with distant metastases, the 3 year survival rate did not depend on the number of other conditions. They concluded that women with severe co-existing diseases would not have a survival advantage because of early diagnosis. One of the reasons for participation may be awareness of the presence of risk factors for breast cancer. If this is true, non-participants will be at less risk of breast cancer. The finding that the non-participant cancer rates did not increase with increasing age, in contrast to the screen-detected cancer rates and interval cancer rates, supports this hypothesis. In women over the age of 65, these non-participant cancer rates were approximately 2 per 1000 rejected invitations per annum, whereas the annual incidence of breast cancer in The Netherlands is about 3.5 per 1000 women (Netherlands Cancer Registry, 1995) . In an earlier study, we also observed that the incidence of breast cancer in the non-participants was lower than would have been expected on the basis of a population without mass screening (Van Dijck et al., 1996) . This means that one explanation for the high incidence in elderly participants, which was 4.5 per 1000 accepted subsequent invitations per annum at ages 65+ (calculated by the summation of screen-detected cancer and interval cancer rates in Table II) , may be that the women who participate at a more advanced age are at greater risk for breast cancer. However, part of the increased incidence in participants may be artificial, because some of the detected cancers may never have become clinically detectable.
As breast cancer incidence increases with increasing age, it was expected that screen-detected cancer rates and interval cancer rates would also show the same pattern. Owing to the slower growth rate (Peer et al., 1993) , it was expected that the ratio of screen-detected to screen-detected plus interval cancers would increase with increasing age. In the 75+ group, however, the proportion of interval cancers was relatively high. In order to find an explanation for this result, we reviewed the previous screening mammograms of 17 out of the 18 interval cancers. Two tumours (12%) had been missed at the previous screening examination; five tumours (29%) were visible in retrospect, but the signs were not specific enough for referral; and ten tumours (59%) had been radiographically occult at the previous screening. These findings are in agreement with the results of our study in 1993 and do not provide an explanation for the high interval cancer rate . Two indicators of stage, i.e. tumour size and lymph node status, were studied. In all age groups, screen-detected tumours were the smallest. Tumours detected at repeat screening had a median size of roughly 15 mm, whereas in non-participants the median size was 25-30 mm. In all age groups there was a similar increase in the proportion of patients with negative axillary nodes due to detection at repeat screening vs clinical detection in non-participants. Thus, it may be concluded that, through periodic screening with mammography in women over the age of 65, breast cancer can be detected at a similar early stage as in those aged 50-64 years.
In summary, our data show that, in women aged 65 years and older, breast cancer can be diagnosed at an earlier stage by mammographic screening. This does not imply that the life expectancy of all screen-detected patients will be longer. First, a larger proportion of the screen-detected cancers may have remained undiagnosed without screening because of the slow growth rate (Peer et al., 1993) . Second, women of 75 have a life expectancy of 11 years and those of 85 of 6 years (Wegman, 1993) . The duration of the detectable preclinical phase in women aged 70 years and older has been estimated at 4.5 years (Peer et al., 1996) . It is thus unlikely that many breast cancer deaths can be prevented in patients screened at age 75 years and older, but the quality of life may be increased if screening can prevent them from having to live for years with metastases.
We conclude that there is reason to continue mammographic screening until at least the age of 75 years. The beneficial effects of mammographic screening on breast cancer mortality and the quality of life may outweigh the negative side-effects until the age when life expectancy is shorter than the detectable preclinical phase of the disease.
